Our latest published phase 1 article in ⁦@NatureMedicine⁩ | Linavonkibart & pembrolizumab in #immunecheckpointblockade -resistant #solidtumors | Enjoyed being part of this effort & this group of PIs #DrugDevelopment #Immunooncology @MoffittNews rdcu.be/eYQz7

Our latest published phase 1 article in ⁦@NatureMedicine⁩ | Linavonkibart & pembrolizumab in #immunecheckpointblockade -resistant solid tumors | Enjoyed part of this effort & this group of PIs #DrugDevelopment #Immunooncology ⁦@MoffittNews⁩ rdcu.be/eYQz7

📢 Special Research Seminar Join us for a @OhioStateMedOnc @OhioStatePIIO faculty candidate talk featuring Dr. No Joon Song! 🧬 "#Tumor-associated #NKcells mediate resistance to #ImmuneCheckpointBlockade therapy" 📅 Tuesday, Sept 9, 2025 🕙 10–11 AM 📍 115 BRT

Computationally Designed Nanobinders as Affinity Ligands in Diagnostic and Therapeutic Applications @JCIM_JCTC 1. A groundbreaking study by Jeon et al. introduces the use of computationally designed nanobinders (DNBs) as a novel alternative to antibodies for detecting protein biomarkers in extracellular vesicles (EVs). This work leverages machine learning to design DNBs, which outperform antibodies in terms of signal intensity, sensitivity, and selectivity. 2. The study highlights the limitations of traditional antibodies, such as cross-reactivity and inconsistent affinity, which can lead to elevated background signals and undermine the accuracy of EV immunoassays. DNBs, with their unique design, minimize these issues. 3. The researchers developed a computational pipeline that includes RoseTTAFold diffusion for generating binder backbones, ProteinMPNN for converting structures into amino acid sequences, and AlphaFold-Multimer for predicting complex structures and evaluating confidence metrics. 4. The PD-L1-targeting DNB demonstrated superior performance in cellular imaging, with up to a 51-fold increase in signal intensity compared to antibodies. It also showed enhanced sensitivity and selectivity in EV analysis, making it a promising tool for cancer diagnostics. 5. Beyond diagnostics, the PD-L1 DNB exhibited therapeutic potential by effectively inhibiting immune checkpoints, suggesting its use in immune checkpoint blockade therapies. 6. The study’s findings underscore the potential of DNBs as a reliable and scalable platform for EV-based diagnostics and therapeutics, potentially advancing the field of cancer care and EV research. 📜Paper: pubs.acs.org/doi/10.1021/jac… #ComputationalBiology #Nanobinders #EVs #CancerDiagnostics #ImmuneCheckpointBlockade

Online!🍹 Integrated multi-omics profiling reveals the role of the #DNAmethylation landscape in shaping biological heterogeneity and clinical behaviour of #metastaticmelanoma Look here💡 jeccr.biomedcentral.com/arti… #ImmuneCheckpointBlockade #DNMTinhibitor

Recently published: Spatial context of #immunecheckpoints as predictors of overall survival in patients with resectable #colorectalcancer independent of standard TNM stages, by Hao Kong et al. doi.org/10.1158/2767-9764.CR… @jiangh7 #ImmuneCheckpointBlockade #openaccess

$CRVS Expecting further revaluation based on pipeline towards $20 ($1B-$1.5B): #ITK inhibition #soquelitinib Ph1 - Atopic dermatitis Ph2 - Solid tumor, #RCC, w/ relapsed #immunecheckpointblockade patients! Ph 3 - #PTCL #A2AR #Ciforadenant Ph2 - Combo RCC w/ anti-PD-1 anti-CTLA-4

Our latest POSTER with @NatRevImmunol explores rationale combinations of #immunecheckpointblockade of #PD1-#PDL1, with other therapies aimed at targeting effector T cells, innate immune regulatory T cells, the #TME & cancer cells. Check it out now! go.nature.com/3WLcCh5

A carrier-free photodynamic bioregulator (CASN) was developed to complement #ImmuneCheckpointBlockade therapy and improve immunotherapeutic efficacy against #TripleNegativeBreastCancer by reprogramming the lactic acid #TumorMicroenvironment. Read: go.acs.org/air

How does #melanoma resist #ImmuneCheckpointBlockade? Researchers at @vib_ccb explored the role of TCF4 and cells in a #mesenchymal-like state. @jchrismarine @pozniak_joanna @DennisPedri 📃 @CellCellPress: bit.ly/3Sbg1Et ▶️: bit.ly/3SlDqTU

Happy to share our thoughts on what the future holds for oncolytic virotherapy. More data forthcoming in conjunction with #immunecheckpointblockade @MarkTysonMD @cgoncology science.org/content/article/…

.@MSKLibrary feature: Novel Genetic Subtypes of Urothelial Carcinoma w/Differential Outcomes on #ImmuneCheckpointBlockade @MichalSarfaty @MSK_DeptOfMed @MSKPathology @AMRegazzi @MSKBiostats @illumina @bengrbm @DrRosenbergMSK @GeneCollector @JCO_ASCO dx.doi.org/10.1200/JCO.22.02…

How do bacteria affect #ImmuneCheckpointBlockade? 🦠 Researchers at @GustaveRoussy investigated if bacteria that rebound after antibiotics are administered affect cancer treatment responses. @ScienceMagazine paper: bit.ly/3PB3gCe Discussion: bit.ly/3CKoohP

Scientists at Tohoku University have discovered a novel approach that improves the efficacy of immune checkpoint blockade and minimizes the associated side effects. #cancer #cancertreatment #immunecheckpointblockade #tohokuuniversity bit.ly/3WPsUVK

A3: Using #machinelearning (#ML), Andrew Patterson and @AuslanderNoam @TheWistar determined genomic predictors of response to #immunecheckpointblockade in #melanoma. Read more @NatureComms: nature.com/articles/s41467-0… #MAMChat23 #MelanomaAwarenessMonth

IL7 genetic variation and toxicity to #ImmuneCheckpointBlockade in patients with #Melanoma nature.com/articles/s41591-0…

Awesome job by PhD candidate @amirmoyo, who represented #MIIProud, #PIIO @Hazemghoneim11 Lab at #AAI2023 with poster titled "Targeting #epigenetic crosstalk that restrains the responses of #ExhaustedTcells to #ImmuneCheckpointBlockade therapy"!!

Our data on #spatial predictors of neoadjuvant #immunecheckpointblockade has just been presented at @AACR's annual meeting. It was such an experience to be part of a session w. other panelists sharing their discoveries on tumor biology using spatial biology in Orlando #AACR23

Autoantibodies reactive to cardiac antigens after concurrent #radiotherapy and #ImmuneCheckpointBlockade are ID’d. Data highlight #Bcells as potential targets to mitigate #cardiotoxicity, in this study by Yan, Hooper, Chen, Lu et al. bit.ly/3NgbQ8p #CancerImmunology

She is showing collaborative work with @MathCancer. They found that immune aggregates from #immunecheckpointblockade limit immune cell trafficking into tumors via computational modeling. #AACR23